George N Ioannou1, Amy S B Bohnert2, Ann M O'Hare3, Edward J Boyko4, Matthew L Maciejewski5, Valerie A Smith6, C Barrett Bowling7, Elizabeth Viglianti8, Theodore J Iwashyna8, Denise M Hynes9, Kristin Berry10. 1. Division of Gastroenterology, University of Washington, and Research and Development and Division of Gastroenterology, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (G.N.I.). 2. Department of Anesthesiology, University of Michigan Medical School, and Center for Clinical Management Research, VA Ann Arbor Health System, Ann Arbor, Michigan (A.S.B.). 3. Nephrology, Veterans Affairs Puget Sound Health Care System, and University of Washington, Seattle, Washington (A.M.O.). 4. General Internal Medicine, Veterans Affairs Puget Sound Health Care System, and University of Washington, Seattle, Washington (E.J.B.). 5. Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham Veterans Affairs Health Care System, and Department of Population Health Sciences, Duke-Margolis Center for Health Policy, and Division of General Internal Medicine, Duke University School of Medicine, Durham, North Carolina (M.L.M.). 6. Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham Veterans Affairs Health Care System, and Department of Population Health Sciences and Division of General Internal Medicine, Duke University School of Medicine, Durham, North Carolina (V.A.S.). 7. Durham Veterans Affairs Geriatric Research Education and Clinical Center, Durham Veterans Affairs Medical Center (VAMC), and Department of Medicine, Duke University, Durham, North Carolina (C.B.B.). 8. Center for Clinical Management Research, VA Ann Arbor Health System, and Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan (E.V., T.J.I.). 9. Center of Innovation to Improve Veteran Involvement in Care, VA Portland Healthcare System, Portland, Oregon, and Health Management and Policy, School of Social and Behavioral Health Sciences, College of Public Health and Human Sciences, and Health Data and Informatics Program, Center for Quantitative Life Sciences, Oregon State University, Corvallis, Oregon (D.M.H.). 10. Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (K.B.).
Abstract
BACKGROUND: The effectiveness of a third mRNA COVID-19 vaccine dose (booster dose) against the Omicron (B.1.1.529) variant is uncertain, especially in older, high-risk populations. OBJECTIVE: To determine mRNA booster vaccine effectiveness (VE) against SARS-CoV-2 infection, hospitalization, and death in the Omicron era by booster type, primary vaccine type, time since primary vaccination, age, and comorbidity burden. DESIGN: Retrospective matched cohort study designed to emulate a target trial of booster vaccination versus no booster, conducted from 1 December 2021 to 31 March 2022. SETTING: U.S. Department of Veterans Affairs health care system. PARTICIPANTS: Persons who had received 2 mRNA COVID-19 vaccine doses at least 5 months earlier. INTERVENTION: Booster monovalent mRNA vaccination (Pfizer-BioNTech's BNT162b2 or Moderna's mRNA-1273) versus no booster. MEASUREMENTS: Booster VE. RESULTS: Each group included 490 838 well-matched persons, who were predominantly male (88%), had a mean age of 63.0 years (SD, 14.0), and were followed for up to 121 days (mean, 79.8 days). Booster VE more than 10 days after a booster dose was 42.3% (95% CI, 40.6% to 43.9%) against SARS-CoV-2 infection, 53.3% (CI, 48.1% to 58.0%) against SARS-CoV-2-related hospitalization, and 79.1% (CI, 71.2% to 84.9%) against SARS-CoV-2-related death. Booster VE was similar for different booster types (BNT162b2 or mRNA-1273), age groups, and primary vaccination regimens but was significantly higher with longer time since primary vaccination and higher comorbidity burden. LIMITATION: Predominantly male population. CONCLUSION: Booster mRNA vaccination was highly effective in preventing death and moderately effective in preventing infection and hospitalization for up to 4 months after administration in the Omicron era. Increased uptake of booster vaccination, which is currently suboptimal, should be pursued to limit the morbidity and mortality of SARS-CoV-2 infection, especially in persons with high comorbidity burden. PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs.
BACKGROUND: The effectiveness of a third mRNA COVID-19 vaccine dose (booster dose) against the Omicron (B.1.1.529) variant is uncertain, especially in older, high-risk populations. OBJECTIVE: To determine mRNA booster vaccine effectiveness (VE) against SARS-CoV-2 infection, hospitalization, and death in the Omicron era by booster type, primary vaccine type, time since primary vaccination, age, and comorbidity burden. DESIGN: Retrospective matched cohort study designed to emulate a target trial of booster vaccination versus no booster, conducted from 1 December 2021 to 31 March 2022. SETTING: U.S. Department of Veterans Affairs health care system. PARTICIPANTS: Persons who had received 2 mRNA COVID-19 vaccine doses at least 5 months earlier. INTERVENTION: Booster monovalent mRNA vaccination (Pfizer-BioNTech's BNT162b2 or Moderna's mRNA-1273) versus no booster. MEASUREMENTS: Booster VE. RESULTS: Each group included 490 838 well-matched persons, who were predominantly male (88%), had a mean age of 63.0 years (SD, 14.0), and were followed for up to 121 days (mean, 79.8 days). Booster VE more than 10 days after a booster dose was 42.3% (95% CI, 40.6% to 43.9%) against SARS-CoV-2 infection, 53.3% (CI, 48.1% to 58.0%) against SARS-CoV-2-related hospitalization, and 79.1% (CI, 71.2% to 84.9%) against SARS-CoV-2-related death. Booster VE was similar for different booster types (BNT162b2 or mRNA-1273), age groups, and primary vaccination regimens but was significantly higher with longer time since primary vaccination and higher comorbidity burden. LIMITATION: Predominantly male population. CONCLUSION: Booster mRNA vaccination was highly effective in preventing death and moderately effective in preventing infection and hospitalization for up to 4 months after administration in the Omicron era. Increased uptake of booster vaccination, which is currently suboptimal, should be pursued to limit the morbidity and mortality of SARS-CoV-2 infection, especially in persons with high comorbidity burden. PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs.
Authors: Miguel A Hernán; Brian C Sauer; Sonia Hernández-Díaz; Robert Platt; Ian Shrier Journal: J Clin Epidemiol Date: 2016-05-27 Impact factor: 6.437
Authors: George N Ioannou; Ann M O'Hare; Kristin Berry; Vincent S Fan; Kristina Crothers; McKenna C Eastment; Emily Locke; Pamela Green; Javeed A Shah; Jason A Dominitz Journal: Clin Infect Dis Date: 2022-02-11 Impact factor: 9.079
Authors: Emma K Accorsi; Amadea Britton; Katherine E Fleming-Dutra; Zachary R Smith; Nong Shang; Gordana Derado; Joseph Miller; Stephanie J Schrag; Jennifer R Verani Journal: JAMA Date: 2022-02-15 Impact factor: 157.335
Authors: Thomas F Osborne; Zachary P Veigulis; David M Arreola; Eliane Röösli; Catherine M Curtin Journal: PLoS One Date: 2020-07-27 Impact factor: 3.240
Authors: George N Ioannou; Emily R Locke; Ann M O'Hare; Amy S B Bohnert; Edward J Boyko; Denise M Hynes; Kristin Berry Journal: Ann Intern Med Date: 2021-12-21 Impact factor: 51.598
Authors: Laith J Abu-Raddad; Hiam Chemaitelly; Houssein H Ayoub; Sawsan AlMukdad; Hadi M Yassine; Hebah A Al-Khatib; Maria K Smatti; Patrick Tang; Mohammad R Hasan; Peter Coyle; Zaina Al-Kanaani; Einas Al-Kuwari; Andrew Jeremijenko; Anvar H Kaleeckal; Ali N Latif; Riyazuddin M Shaik; Hanan F Abdul-Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al-Kuwari; Adeel A Butt; Hamad Eid Al-Romaihi; Mohamed H Al-Thani; Abdullatif Al-Khal; Roberto Bertollini Journal: N Engl J Med Date: 2022-03-09 Impact factor: 91.245
Authors: Mark G Thompson; Karthik Natarajan; Stephanie A Irving; Elizabeth A Rowley; Eric P Griggs; Manjusha Gaglani; Nicola P Klein; Shaun J Grannis; Malini B DeSilva; Edward Stenehjem; Sarah E Reese; Monica Dickerson; Allison L Naleway; Jungmi Han; Deepika Konatham; Charlene McEvoy; Suchitra Rao; Brian E Dixon; Kristin Dascomb; Ned Lewis; Matthew E Levy; Palak Patel; I-Chia Liao; Anupam B Kharbanda; Michelle A Barron; William F Fadel; Nancy Grisel; Kristin Goddard; Duck-Hye Yang; Mehiret H Wondimu; Kempapura Murthy; Nimish R Valvi; Julie Arndorfer; Bruce Fireman; Margaret M Dunne; Peter Embi; Eduardo Azziz-Baumgartner; Ousseny Zerbo; Catherine H Bozio; Sue Reynolds; Jill Ferdinands; Jeremiah Williams; Ruth Link-Gelles; Stephanie J Schrag; Jennifer R Verani; Sarah Ball; Toan C Ong Journal: MMWR Morb Mortal Wkly Rep Date: 2022-01-21 Impact factor: 35.301
Authors: Vincent S Fan; Jason A Dominitz; McKenna C Eastment; Emily Locke; Pamela Green; Kristin Berry; Ann M O'Hare; Javeed A Shah; Kristina Crothers; George N Ioannou Journal: Clin Infect Dis Date: 2020-10-27 Impact factor: 9.079